Methallenestril

Methallenestril
Clinical data
Trade namesCur-men, Ercostrol, Geklimon, Novestrine, Vallestril (also spelled Vallestrol or Vallestryl)
Other namesMethallenoestril; Methallenestrol; Methallenoestrol; Horeau's acid; Allenestrol 6-methyl ether; α,α-Dimethyl-β-ethylallenolic acid 6-methyl ether; β-Ethyl-6-methoxy-α,α-dimethyl-2-naphthalenepropionic acid
Routes of
administration		By mouth
Drug classNonsteroidal estrogen
ATC code
Identifiers
  • 3-(6-Methoxynaphthalen-2-yl)-2,2-dimethylpentanoic acid
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
ECHA InfoCard100.007.485 Edit this at Wikidata
Chemical and physical data
FormulaC18H22O3
Molar mass286.371 g·mol−1
3D model (JSmol)
  • CCC(c1ccc2cc(OC)ccc2c1)C(C)(C)C(=O)O
  • InChI=1S/C18H22O3/c1-5-16(18(2,3)17(19)20)14-7-6-13-11-15(21-4)9-8-12(13)10-14/h6-11,16H,5H2,1-4H3,(H,19,20)
  • Key:KHLJKRBMZVNZOC-UHFFFAOYSA-N
  (verify)

Methallenestril (INNTooltip International Nonproprietary Name) (brand names Cur-men, Ercostrol, Geklimon, Novestrine, Vallestril), also known as methallenoestril (BANTooltip British Approved Name) and as methallenestrol, as well as Horeau's acid,[1][2] is a synthetic nonsteroidal estrogen and a derivative of allenolic acid and allenestrol (specifically, a methyl ether of it) that was formerly used to treat menstrual issues but is now no longer marketed.[3][4][5][6] It is a seco-analogue of bisdehydrodoisynolic acid, and although methallenestril is potently estrogenic in rats, in humans it is only weakly so in comparison.[7] Vallestril was a brand of methallenestril issued by G. D. Searle & Company in the 1950s.[8] Methallenestril is taken by mouth.[9] By the oral route, a dose of 25 mg methallenestril is approximately equivalent to 1 mg diethylstilbestrol, 4 mg dienestrol, 20 mg hexestrol, 25 mg estrone, 2.5 mg conjugated estrogens, and 0.05 mg ethinylestradiol.[9]

  1. ^ Heftmann E (1970). Steroid Biochemistry. Academic Press. p. 144. ISBN 9780123366504.
  2. ^ Dodds EC (March 1949). "Synthetic oestrogens". The Journal of Pharmacy and Pharmacology. 1 (3): 137–147. doi:10.1111/j.2042-7158.1949.tb12391.x. PMID 18114509. S2CID 221921908.
  3. ^ Ganellin CR, Triggle DJ (21 November 1996). Dictionary of Pharmacological Agents. CRC Press. pp. 1295–. ISBN 978-0-412-46630-4.
  4. ^ Morton IK, Hall JM (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 177–. ISBN 978-94-011-4439-1.
  5. ^ Thomas JA, Keenan EJ (1986). "Estrogens and Estrogenic Compounds". Principles of Endocrine Pharmacology. Springer Science & Business Media. p. 136. ISBN 978-1-4684-5036-1.
  6. ^ Herbai G, Ljunghall S (1983). "Normalization of hypercalcaemia of primary hyperparathyroidism by treatment with methallenestril, a synthetic oestrogen with low oestrogenicity". Urologia Internationalis. 38 (6): 371–373. doi:10.1159/000280925. PMID 6659184.
  7. ^ Kirk RE, Othmer DF (1980). Encyclopedia of chemical technology. Wiley. p. 670. ISBN 978-0-471-02065-3.
  8. ^ Catalog of Copyright Entries: Third Series. Vol. 17. Copyright Office, Library of Congress. July–December 1963. pp. 1984–.
  9. ^ a b Swyer GI (April 1959). "The oestrogens". British Medical Journal. 1 (5128): 1029–1031. doi:10.1136/bmj.1.5128.1029. PMC 1993181. PMID 13638626.